Valneva : Capital increase of € 60m
>Financed to achieve profitability - The company announces the launch of a capital increase of c. € 60m through the issuance of 22.6 million shares at a price of € 2.66, i.e. a discount of c. 15% vs the last closing price. Valneva plans to use the proceeds to fund the paediatric phase III trial and phase IV trials of its chikungunya vaccine as well as the anticipated phase 2 programmes for the Shigellosis and Zika virus vaccine candidates. A portion of the financing w...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.